Novartis: raises 2023 earnings target
(CercleFinance.com) - On announcing its results, Novartis has raised its 2023 guidance for core operating income, which it now expects to grow in a mid-to-high double-digit range (instead of low-to-mid double-digit range), while net sales are still expected to grow in the high single-digits.
In Q3, the Swiss pharmaceuticals group posted core EPS of $1.74 and core operating profit of just over $4.4bn, up 29% and 21% respectively at constant exchange rates (CER).
Meanwhile, net sales rose by 12% at constant exchange rates to almost $11.8bn, underpinned by the continued excellent performance of Kesimpta (+124%), Entresto (+31%), Kisqali (+76%), Pluvicto (+217%) and Scemblix (+157%), it says.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
In Q3, the Swiss pharmaceuticals group posted core EPS of $1.74 and core operating profit of just over $4.4bn, up 29% and 21% respectively at constant exchange rates (CER).
Meanwhile, net sales rose by 12% at constant exchange rates to almost $11.8bn, underpinned by the continued excellent performance of Kesimpta (+124%), Entresto (+31%), Kisqali (+76%), Pluvicto (+217%) and Scemblix (+157%), it says.
Copyright (c) 2023 CercleFinance.com. All rights reserved.